Huber S, Spycher M, Lechner-Scott J, Bellaiche Y, Steck A J, Kappos L
Neurologische Universitätklinik, Kantonsspital Basel.
Schweiz Med Wochenschr. 1996 Aug 31;126(35):1475-81.
Recombinant interferon beta-1b has been registered with the Swiss health authorities since August 1995. Due to a special arrangement with health insurances it has been possible to prescribe this medication since spring 1995. We report on our experience with the first 30 consecutively treated multiple sclerosis patients. Indication, adverse event profile and clinical response to treatment are described. The most common side effects were local injection site reactions (63%), influenza-like symptoms (50%) and fatigue (33%). As compared to the prestudy period we observed a 49% reduction in the exacerbation rate. Compliance was excellent, possibly due to strict selection and extensive information about possible effects and side effects.
重组干扰素β-1b自1995年8月起已在瑞士卫生当局注册。由于与健康保险的特殊安排，自1995年春季起就可以开这种药。我们报告了连续治疗的首批30例多发性硬化症患者的经验。描述了治疗的适应症、不良事件概况和临床反应。最常见的副作用是局部注射部位反应（63%）、流感样症状（50%）和疲劳（33%）。与研究前时期相比，我们观察到病情加重率降低了49%。依从性极佳，这可能是由于严格的筛选以及关于可能的疗效和副作用的详细信息。
